# Koumiss (Fermented Mare’s Milk) as a Functional Food: Bioactive Proteins, Peptides, and Future Perspectives

**Authors:** Borhan Shokrollahi, Jae-Young Choi, Miyoung Won, Eun-Tae Kim, Seung-Eun Lee, Jun-Sang Ham

PMC · DOI: 10.3390/foods14223954 · Foods · 2025-11-18

## TL;DR

Koumiss, a fermented mare's milk, contains bioactive compounds that may improve digestion, immunity, and heart health, with potential for development as a functional food.

## Contribution

The paper highlights the unique bioactive profile of koumiss and proposes technological strategies to enhance its functional properties.

## Key findings

- Koumiss contains over 2300 peptides and 350 metabolites with ACE-inhibitory and antimicrobial activities.
- Preclinical studies suggest koumiss may benefit lipid metabolism and gut health.
- Technological methods like microencapsulation can improve bioactive stability in koumiss.

## Abstract

Fermented mare’s milk, or koumiss, has been consumed for centuries across Central Asia for its nutritional and therapeutic value. Mare’s milk differs from bovine milk by its near 1:1 casein-to-whey ratio, high lysozyme and lactoferrin, abundant immunoglobulins, and low β-lactoglobulin, which enhance digestibility, reduce allergenicity, and increase antimicrobial activity. During fermentation, lactic acid bacteria and yeasts transform this substrate into a reservoir of bioactive proteins, peptides, and metabolites. Multi-omics profiling has identified more than 2300 peptides and over 350 metabolites, including sequences with angiotensin-converting enzyme (ACE)-inhibitory, antioxidant, antimicrobial, and immunomodulatory activities. Preclinical and limited clinical data indicate potential benefits for lipid metabolism, cardiovascular function, and gut health. Mechanistically, these effects appear to arise from synergistic actions of native proteins, fermentation-derived peptides, and probiotic consortia. Technological advances such as rational starter culture design, controlled proteolysis, and microencapsulation offer strategies to enhance bioactive yield and stability. However, standardized fermentation protocols and clinical validation remain necessary to position koumiss as a scientifically supported functional food.

## Linked entities

- **Proteins:** lysozyme (lysozyme 1-like), tf.S (transferrin S homeolog)

## Full-text entities

- **Genes:** ACE (angiotensin I converting enzyme) [NCBI Gene 509484], LOC781146 (lysozyme) [NCBI Gene 781146], LTF (lactotransferrin) [NCBI Gene 280846] {aka Lf}, PAEP (progestagen-associated endometrial protein) [NCBI Gene 280838] {aka BLG, LGB}
- **Chemicals:** lactic acid (MESH:D019344), lipid (MESH:D008055)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Bos taurus (bovine, species) [taxon 9913]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12652487/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12652487/full.md

## References

225 references — full list in the complete paper: https://tomesphere.com/paper/PMC12652487/full.md

---
Source: https://tomesphere.com/paper/PMC12652487